Cargando…
Cleaved CDCP1 marks the spot: a neoepitope for RAS-driven cancers
A challenge in cancer treatment is targeting cancer cells while sparing normal cells. Thus, identifying cancer-specific neoepitopes is an active research area. Neoepitopes are generated by the accumulation of mutations; however, deadly cancer types, including pancreatic cancer, have a low mutational...
Autores principales: | Donahue, Katelyn L., Pasca di Magliano, Marina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843638/ https://www.ncbi.nlm.nih.gov/pubmed/35166242 http://dx.doi.org/10.1172/JCI157168 |
Ejemplares similares
-
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers
por: Lim, Shion A., et al.
Publicado: (2022) -
Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
por: Arnaud, Marion, et al.
Publicado: (2023) -
Mass spectrometry–driven exploration reveals nuances of neoepitope-driven tumor rejection
por: Ebrahimi-Nik, Hakimeh, et al.
Publicado: (2019) -
The neoepitope landscape in pediatric cancers
por: Chang, Ti-Cheng, et al.
Publicado: (2017) -
Pan-cancer analysis of neoepitopes
por: Teku, Gabriel N., et al.
Publicado: (2018)